在CKD中SGLT2抑制剂:它们对所有患者真的有效吗?
1Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂对许多慢性病 (CKD) 患者有好处,但它们在患有非糖尿病CKD的瘦个体中的有效性尚不确定. 需要进行进一步的试验,以澄清SGLT2抑制剂在各种CKD亚组中的疗效.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 抑制剂是减缓慢性病 (CKD) 进展和减少心血管事件的已确立治疗方法,特别是在糖尿病和肥胖患者中.
- 目前的证据主要来自于患有晚期CKD的超重或肥胖患者的试验,其中保留和球过等机制是突出的.
研究的目的:
- 评估SGLT2抑制剂在各种CKD亚组中的不确定的疗效,特别是在瘦身,非糖尿病患者中.
- 调查SGLT2抑制剂的益处是否取决于体重指数 (BMI) 和疾病特异性进展机制.
主要方法:
- 审查现有的临床试验数据和新出现的证据,包括动物研究和SGLT2表达的分子数据.
- 分析影响SGLT2抑制剂疗效的因素,如BMI,潜在的CKD病因 (例如遗传,免疫媒介) 和疾病驱动因素.
主要成果:
- 新出现的证据表明,SGLT2抑制剂可能在瘦个体 (BMI < 25) 中效果较差,其CKD可能源于炎症,自身免疫或遗传因素,而不是过.
- 动物研究表明,在某些遗传和免疫媒介病中,对SGLT2抑制剂的保护有限.
- SGLT2的表达主要在近道管中,这表明非过机制驱动的CKD对CKD的影响有限.
结论:
- 在瘦身,非糖尿病慢性病患者中SGLT2抑制剂的作用尚不清楚,需要专门的临床试验.
- 需要个性化治疗策略,考虑CKD亚组和个体患者特征,以获得最佳的治疗结果.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
155
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
155
Oral Hypoglycemic Agents: Biguanides and Glitazones
149
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
149
Oral Hypoglycemic Agents: Glinides
127
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
127
Glucagon-like Receptor Agonists
289
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
289
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
141
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
141
Glucose Transporters
22.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.3K


